PMID- 32848939
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Electronic)
IS  - 1664-0640 (Linking)
VI  - 11
DP  - 2020
TI  - Mismatch Negativity Predicts Remission and Neurocognitive Function in Individuals 
      at Ultra-High Risk for Psychosis.
PG  - 770
LID - 10.3389/fpsyt.2020.00770 [doi]
LID - 770
AB  - BACKGROUND: In the early intervention in psychosis, ultra-high risk (UHR) 
      criteria have been used to identify individuals who are prone to develop 
      psychosis. Although the transition rate to psychosis in individuals at UHR is 10% 
      to 30% within several years, some individuals at UHR present with poor prognoses 
      even without transition occurring. Therefore, it is important to identify 
      biomarkers for predicting the prognosis of individuals at UHR, regardless of 
      transition. We investigated whether mismatch negativity (MMN) in response to both 
      duration deviant stimuli (dMMN) and frequency deviant stimuli (fMMN) could 
      predict prognosis, including remission and neurocognitive function in individuals 
      at UHR. MATERIALS AND METHODS: Individuals at UHR (n = 24) and healthy controls 
      (HC; n = 18) participated in this study. In an auditory oddball paradigm, both 
      dMMN and fMMN were measured at baseline. Remission and neurocognitive function 
      after > 180 days were examined in the UHR group. Remission from UHR was defined 
      as functional and symptomatic improvement using the Global Assessment of 
      Functioning (GAF) score and Scale of Prodromal Symptoms (SOPS) positive 
      subscales. Neurocognitive function was measured using the Brief Assessment of 
      Cognition in Schizophrenia (BACS). We examined differences in MMN amplitude at 
      baseline between those who achieved remission (remitters) and those who did not 
      (non-remitters). Multiple regression analyses were performed to identify 
      predictors for functioning, positive symptoms, and neurocognitive function. 
      RESULTS: Compared with the HC group, the UHR group had a significantly attenuated 
      dMMN amplitude (p = 0.003). In the UHR group, GAF scores significantly improved 
      during the follow-up period (mean value 47.1 to 55.5, p = 0.004). The dMMN 
      amplitude at baseline was significantly larger in the remitter (n = 6) than in 
      the non-remitter group (n = 18) (p = 0.039). The total SOPS positive subscale 
      scores and fMMN amplitude at baseline could predict BACS attention subscore at 
      the follow-up point (SOPS positive subscales, p = 0.030; fMMN, p = 0.041). 
      CONCLUSION: Our findings indicate that dMMN and fMMN predicted remission and 
      neurocognitive function, respectively, in individuals at UHR, which suggests that 
      there are both promising biomarker candidates for predicting prognosis in 
      individuals at UHR.
CI  - Copyright (c) 2020 Fujioka, Kirihara, Koshiyama, Tada, Nagai, Usui, Morita, 
      Kawakami, Morita, Satomura, Koike, Suga, Araki and Kasai.
FAU - Fujioka, Mao
AU  - Fujioka M
AD  - Department of Neuropsychiatry, Graduate School of Medicine, The University of 
      Tokyo, Tokyo, Japan.
FAU - Kirihara, Kenji
AU  - Kirihara K
AD  - Department of Neuropsychiatry, Graduate School of Medicine, The University of 
      Tokyo, Tokyo, Japan.
FAU - Koshiyama, Daisuke
AU  - Koshiyama D
AD  - Department of Neuropsychiatry, Graduate School of Medicine, The University of 
      Tokyo, Tokyo, Japan.
AD  - Department of Psychiatry, University of California San Diego, La Jolla, CA, 
      United States.
FAU - Tada, Mariko
AU  - Tada M
AD  - Department of Neuropsychiatry, Graduate School of Medicine, The University of 
      Tokyo, Tokyo, Japan.
AD  - The International Research Center for Neurointelligence (WPI-IRCN), University of 
      Tokyo Institutes for Advanced Study (UTIAS), The University of Tokyo, Tokyo, 
      Japan.
FAU - Nagai, Tatsuya
AU  - Nagai T
AD  - Department of Neuropsychiatry, Graduate School of Medicine, The University of 
      Tokyo, Tokyo, Japan.
AD  - Department of Psychiatry, Kawamuro Memorial Hospital, Joetsu, Japan.
FAU - Usui, Kaori
AU  - Usui K
AD  - Department of Neuropsychiatry, Graduate School of Medicine, The University of 
      Tokyo, Tokyo, Japan.
FAU - Morita, Susumu
AU  - Morita S
AD  - Department of Neuropsychiatry, Graduate School of Medicine, The University of 
      Tokyo, Tokyo, Japan.
FAU - Kawakami, Shintaro
AU  - Kawakami S
AD  - Department of Neuropsychiatry, Graduate School of Medicine, The University of 
      Tokyo, Tokyo, Japan.
FAU - Morita, Kentaro
AU  - Morita K
AD  - Department of Rehabilitation, Graduate School of Medicine, The University of 
      Tokyo, Tokyo, Japan.
FAU - Satomura, Yoshihiro
AU  - Satomura Y
AD  - Department of Neuropsychiatry, Graduate School of Medicine, The University of 
      Tokyo, Tokyo, Japan.
FAU - Koike, Shinsuke
AU  - Koike S
AD  - Department of Neuropsychiatry, Graduate School of Medicine, The University of 
      Tokyo, Tokyo, Japan.
AD  - The International Research Center for Neurointelligence (WPI-IRCN), University of 
      Tokyo Institutes for Advanced Study (UTIAS), The University of Tokyo, Tokyo, 
      Japan.
AD  - University of Tokyo Institute for Diversity and Adaptation of Human Mind 
      (UTIDAHM), The University of Tokyo, Tokyo, Japan.
AD  - Center for Evolutionary Cognitive Sciences, Graduate School of Art and Sciences, 
      The University of Tokyo, Tokyo, Japan.
AD  - UTokyo Center for Integrative Science of Human Behaviour (CiSHuB), The University 
      of Tokyo, Tokyo, Japan.
FAU - Suga, Motomu
AU  - Suga M
AD  - Department of Neuropsychiatry, Graduate School of Medicine, The University of 
      Tokyo, Tokyo, Japan.
AD  - Graduate School of Clinical Psychology, Teikyo Heisei University, Tokyo, Japan.
FAU - Araki, Tsuyoshi
AU  - Araki T
AD  - Department of Neuropsychiatry, Graduate School of Medicine, The University of 
      Tokyo, Tokyo, Japan.
FAU - Kasai, Kiyoto
AU  - Kasai K
AD  - Department of Neuropsychiatry, Graduate School of Medicine, The University of 
      Tokyo, Tokyo, Japan.
AD  - The International Research Center for Neurointelligence (WPI-IRCN), University of 
      Tokyo Institutes for Advanced Study (UTIAS), The University of Tokyo, Tokyo, 
      Japan.
AD  - University of Tokyo Institute for Diversity and Adaptation of Human Mind 
      (UTIDAHM), The University of Tokyo, Tokyo, Japan.
AD  - UTokyo Center for Integrative Science of Human Behaviour (CiSHuB), The University 
      of Tokyo, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200803
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC7416637
OTO - NOTNLM
OT  - longitudinal study
OT  - mismatch negativity
OT  - neurocognitive function
OT  - remission
OT  - ultra-high risk for psychosis
EDAT- 2020/08/28 06:00
MHDA- 2020/08/28 06:01
PMCR- 2020/08/03
CRDT- 2020/08/28 06:00
PHST- 2020/03/18 00:00 [received]
PHST- 2020/07/21 00:00 [accepted]
PHST- 2020/08/28 06:00 [entrez]
PHST- 2020/08/28 06:00 [pubmed]
PHST- 2020/08/28 06:01 [medline]
PHST- 2020/08/03 00:00 [pmc-release]
AID - 10.3389/fpsyt.2020.00770 [doi]
PST - epublish
SO  - Front Psychiatry. 2020 Aug 3;11:770. doi: 10.3389/fpsyt.2020.00770. eCollection 
      2020.